Reviewing the Rationale for and Reducing Cross-Shareholdings
First written in FY2019. 5 of 7 entries say "Advanced", first in FY2020. Latest entry: FY2025.
- FY2025AdvancedAnnual report
「Regarding whether to continue its policy-held shareholdings, the company examined, using the aforementioned method, the investment shares held by the company and its group companies as of the end of December 2025 at a Board of Directors meeting held in January 2026.」
The company continued its annual review of the economic rationale and strategic value of each policy-held shareholding, and Otsuka Pharmaceutical sold 16 listed stocks and other holdings. - FY2024AdvancedAnnual report
「Regarding whether to continue its policy-held shareholdings, the company examined, using the aforementioned method, the investment shares held by the company and its group companies as of the end of December 2024 at a Board of Directors meeting held in January 2025.」
The company continued its annual review of the economic rationale and strategic value of each individual holding, and Otsuka Pharmaceutical sold 13 listed stocks and other holdings. - FY2023AdvancedAnnual report
「Regarding whether to continue its policy-held shareholdings, the company examined, using the aforementioned method, the investment shares held by the company and its group companies as of the end of December 2023 at a Board of Directors meeting held in January 2024.」
The company continued its annual review of the economic rationale and strategic value of each individual holding, and the filing company and Otsuka Pharmaceutical sold multiple stocks. - FY2022AdvancedAnnual report
「Regarding whether to continue its policy-held shareholdings, the company examined, using the aforementioned method, the investment shares held by the company and its group companies as of the end of December 2022 at a Board of Directors meeting held in January 2023.」
The company continues the annual Board of Directors review of the economic rationale and strategic value of each holding, and also sold multiple stocks during the fiscal year. - FY2021RestatedAnnual report
「Regarding whether to continue its policy-held shareholdings, the company examined, using the aforementioned method, the investment shares held by the company and its group companies as of the end of December 2021 at a Board of Directors meeting held in January 2022.」
The company continues its policy of annually reviewing the economic rationale and strategic value of each policy-held shareholding at Board of Directors meetings. - FY2020AdvancedAnnual report
「Regarding whether to continue its policy-held shareholdings, the company examined, using the aforementioned method, the investment shares held by the company and its group companies as of the end of December 2020 at a Board of Directors meeting held in February 2021.」
For policy-held shares, the Board of Directors examined the economic rationale and strategic value of each individual holding, and Otsuka Pharmaceutical also sold 4 stocks for ¥2,394 million during the fiscal year. - FY2019First statedAnnual report
「After examining the holdings from both economic-rationality and qualitative strategic-value perspectives, the company proceeded with reductions as the strategic value of certain holdings diminished. In fiscal 2019, it sold 43 stocks for ¥1,242 million. It also identified multiple stocks for which reductions are under consideration.」
For policy-held shares, the Board of Directors examined the economic rationale and strategic value of each holding, and 43 stocks were sold for ¥1,242 million in fiscal 2019. The company stated that it would continue considering reductions in certain holdings.